AFP and liver disorder: The study enrolled 292 patients with BCLC stage B or C disease that was refractory or not amenable to locoregional therapy, with Child–Pugh class A liver disease and serum AFP concentrations of 400 ng/mL or higher, and who had received previous treatment only with sorafenib.